Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study

BMC Infectious Diseases

Maarten F Schim van der Loeff²  Roel A Coutinho¹  Titia Heijman³  Dominique WM Verhagen⁶  Audrey J King⁵  Chris JLM Meijer⁴  Marianne AB van der Sande¹  Sofie H Mooij²  Fleur van Aar⁵ 

[1] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands;Center for Infection and Immunity Amsterdam (CINIMA), Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands;Cluster of Infectious Diseases, Public Health Service of Amsterdam (GGD), Amsterdam, The Netherlands;Department of Pathology, Vrije Universiteit-University Medical Center (VUmc), Amsterdam, The Netherlands;Centre for Infectious Disease Control, National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM), Bilthoven, 3720BA, The Netherlands;Department of Internal Medicine, Jan van Goyen Medical Center, Amsterdam, The Netherlands

关键词: MSM;    HIV;    Clearance;    Incidence;    HPV;    Oral;   

Others  :  1090137
DOI  :  10.1186/s12879-014-0668-z

 received in 2014-08-21, accepted in 2014-11-26,  发布年份 2014

【 摘 要 】

Background

Our aim was to compare the 12-month incidence and clearance of oral high-risk HPV infection between HIV-infected men who have sex with men (MSM) and HIV-negative MSM.

Methods

MSM aged 18 years or older were recruited in Amsterdam, the Netherlands. Questionnaire data and oral-rinse and gargle samples were collected at baseline, and after 6 and 12 months. HPV DNA was genotyped using the SPF₁₀-PCR & DEIA-LiPA₂₅ system (version 1). Determinants of oral HPV incidence and clearance were explored using Cox and logistic regression analyses respectively.

Results

433 HIV-negative and 290 HIV-infected MSM were included in these analyses. The median follow-up time per participant was 12 months (range 3–15). During follow-up, 114 incident oral high-risk HPV infections were observed. The incidence rate of HPV-16 was 3.5/1000 person-months (PM) in HIV-infected and 0.9/1000 PM in HIV-negative MSM (IRR 4.1; 95% CI 1.3-13.2). The incidence rates of other high-risk HPV types ranged between 1.3-3.5/1000 PM in HIV-infected and 0.0-1.1/1000 PM in HIV-negative MSM. In multivariable analyses, HIV infection (adjusted hazard ratio [aHR] 3.8; 95% CI 2.3-6.2) and a higher number of recent oral sex partners (aHR 2.4 for ≥8 partners compared to ≤2; 95% CI 1.4-4.2) were associated with HPV incidence. Of the 111 baseline oral high-risk infections, 59 (53.2%) were cleared. In multivariable analyses, only a higher number of recent oral sex partners was associated with HPV clearance (adjusted odds ratio 3.4 for ≥8 compared to ≤2 partners; 95% CI 1.3-9.0).

Conclusions

The incidence rate of oral high-risk HPV infection was higher in HIV-infected MSM and in those with a higher number of recent oral sex partners. Just over half of the oral high-risk HPV infections at baseline were cleared after 12 months, with a higher likelihood of clearance among MSM reporting higher numbers of recent oral sex partners, but no difference by HIV status.

【 授权许可】

   
2014 van Aar et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V: A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
• [2]Kreimer AR, Bhatia RK, Messeguer AL, Gonzalez P, Herrero R, Giuliano AR: Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010, 37(6):386-391.
• [3]Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, Wiley DJ, Minkoff H, Reddy S, Stammer EE, Gillison ML, D’Souza G: Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 2012, 21(1):122-133.
• [4]Mooij SH, Boot HJ, Speksnijder AG, Stolte IG, Meijer CJ, Snijders PJ, Verhagen DW, King AJ, de Vries HJ, Quint WG, van der Sande MA, Schim van der Loeff MF: Oral human papillomavirus infection in HIV-negative and HIV-infected MSM. Aids 2013, 27(13):2117-2128.
• [5]Kreimer AR, Pierce Campbell CM, Lin HY, Fulp W, Papenfuss MR, Abrahamsen M, Hildesheim A, Villa LL, Salmeron JJ, Lazcano-Ponce E, Giuliano AR: Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013, 382(9895):877-887.
• [6]Beachler DC, D’Souza G, Sugar EA, Xiao W, Gillison ML: Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 2013, 208(2):330-339.
• [7]Videla S, Darwich L, Canadas MP, Coll J, Pinol M, Garcia-Cuyas F, Molina-Lopez RA, Cobarsi P, Clotet B, Sirera G: Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 2013, 40(1):3-10.
• [8]Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, O’Reilly S, Lee SK, Fu Xi L, Koutsky LA: Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis 2012, 39(11):860-867.
• [9]D’Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML: Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009, 199(9):1263-1269.
• [10]Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK: Prevalence of oral HPV infection in the United States, 2009–2010. Jama 2012, 307(7):693-703.
• [11]Ong JJ, Read TR, Vodstrcil LA, Walker S, Chen M, Bradshaw CS, Garland SM, Tabrizi SN, Cornall A, Grulich A, Hocking J, Fairley CK: Detection of oral human papillomavirus in HIV-positive men who have sex with men 3 years after baseline: a follow up cross-sectional study. PLoS One 2014, 9(7):e102138.
• [12]Darwich L, Canadas MP, Videla S, Coll J, Molina-Lopez RA, Cobarsi P, Sirera G, Clotet B: Oral human papillomavirus type-specific infection in HIV-infected men: a prospective cohort study among men who have sex with men and heterosexual men. Clin Microbiol Infect 2014, 20(9):O585-O589.
• [13]Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67.
• [14]Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI: HIV infection and the risk of cancers with and without a known infectious cause. Aids 2009, 23(17):2337-2345.
• [15]Mooij SH, Boot HJ, Speksnijder AG, Meijer CJ, King AJ, Verhagen DW, de Vries HJ, Quint WG, Molijn A, de Koning MN, van der Sande MA, van der Loeff MF: Six-month incidence and persistence of oral HPV infection in HIV-negative and HIV-infected men who have sex with men. PLoS One 2014, 9(6):e98955.
• [16]Molijn A, Kleter B, Quint W, van Doorn LJ: Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005, 32(Suppl 1):S43-S51.
• [17]Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, Massad LS, Watts DH, Kuniholm MH, Anastos K, Levine AM, Fazzari M, D’Souza G, Plankey M, Palefsky JM, Strickler HD: Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010, 19(1):159-169.
• [18]van Aar F, Mooij SH, van der Sande MA, Speksnijder AG, Stolte IG, Meijer CJ, Verhagen DW, King AJ, de Vries HJ, van der Loeff MF S: Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. Aids 2013, 27(18):2921-2931.
• [19]Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008, 100(6):407-420.
• [20]Read TR, Hocking JS, Vodstrcil LA, Tabrizi SN, McCullough MJ, Grulich AE, Garland SM, Bradshaw CS, Chen MY, Fairley CK: Oral human papillomavirus in men having sex with men: risk-factors and sampling. PLoS One 2012, 7(11):e49324.
• [21]Ong JJ, Read T, Chen M, Walker S, Law M, Bradshaw C, Garland SM, Tabrizi SN, Cornall A, Grulich A, Hocking J, Fairley CK: Improving oral human papillomavirus detection using toothbrush sampling in HIV-positive men who have sex with men. J Clin Microbiol 2014, 52(6):2206-2209.
• [22]Bui TC, Markham CM, Ross MW, Mullen PD: Examining the association between oral health and oral HPV infection. Cancer Prev Res (Phila) 2013, 6(9):917-924.
• [23]Hang D, Liu F, Liu M, He Z, Sun M, Liu Y, Li J, Pan Y, Ning T, Guo C, Liang Y, Xu R, Zhang L, Cai H, Ke Y: Oral human papillomavirus infection and its risk factors among 5,410 healthy adults in china, 2009–2011. Cancer Epidemiol Biomarkers Prev 2014, 23(10):2101-2110.
• [24]Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29(32):4294-4301.
• [25]Hocking JS, Stein A, Conway EL, Regan D, Grulich A, Law M, Brotherton JM: Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer 2011, 104(5):886-891.
• [26]Rietbergen MM, Leemans CR, Bloemena E, Heideman DA, Braakhuis BJ, Hesselink AT, Witte BI, de Jong RJ B, Meijer CJ, Snijders PJ, Brakenhoff RH: Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer 2013, 132(7):1565-1571.